INT148291

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.61
First Reported 2006
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 9
Total Number 10
Disease Relevance 6.37
Pain Relevance 0.70

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (CSF3) extracellular region (CSF3) enzyme binding (CSF3)
Anatomy Link Frequency
granulocyte 4
superior 1
neutrophil 1
CSF3 (Homo sapiens)
Pain Link Frequency Relevance Heat
cytokine 42 100.00 Very High Very High Very High
antagonist 7 100.00 Very High Very High Very High
Inflammatory response 5 94.32 High High
depression 3 79.52 Quite High
headache 7 78.68 Quite High
Paresthesia 2 74.80 Quite High
Inflammation 58 67.44 Quite High
agonist 1 52.00 Quite High
imagery 60 50.00 Quite Low
Potency 5 49.44 Quite Low
Disease Link Frequency Relevance Heat
Syndrome 430 99.82 Very High Very High Very High
Sepsis 2 99.60 Very High Very High Very High
Hyperplasia 17 99.24 Very High Very High Very High
Skin Diseases 118 99.12 Very High Very High Very High
Acute-phase Reaction 2 98.28 Very High Very High Very High
Myelodysplastic Syndromes 11 98.22 Very High Very High Very High
Pancreatitis 5 97.20 Very High Very High Very High
Hematologic Neoplasms 22 96.84 Very High Very High Very High
INFLAMMATION 51 93.92 High High
Fever 22 89.84 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
RESULTS: Of the 61 patients, 42 (69%) did not require prophylactic GCSF.
Neg (not) Positive_regulation (require) of GCSF
1) Confidence 0.61 Published 2008 Journal Breast Cancer Res. Treat. Section Body Doc Link 18060493 Disease Relevance 0.08 Pain Relevance 0
However, in our experience, the Gd-enhancement of the GCSF-treated, markedly hypercellular marrow and neoplastic marrow in patients with hematologic malignancies shows considerable overlap and is of limited clinical value for a definitive differentiation of these entities.
Positive_regulation (enhancement) of GCSF associated with hematologic neoplasms and hyperplasia
2) Confidence 0.45 Published 2006 Journal Eur Radiol Section Body Doc Link PMC1797072 Disease Relevance 0.50 Pain Relevance 0
The induction of a systemic cytokine response, including elevated plasma levels of interleukin (IL)-1 receptor antagonist (IL-1ra), IL-6, IL-8, IL-10, and granulocyte colony-stimulating factor (G-CSF), following intense physical activity, is well documented [1-5].
Positive_regulation (induction) of granulocyte colony-stimulating factor in granulocyte associated with antagonist and cytokine
3) Confidence 0.45 Published 2010 Journal BMC Med Genet Section Body Doc Link PMC2837019 Disease Relevance 0.50 Pain Relevance 0.32
PATIENTS AND METHODS: Patients receiving accelerated (dose dense) paclitaxel 175 mg/m2 2 weekly for 4 courses as adjuvant/neoadjuvant treatment for early breast cancer were treated electively without prophylactic GCSF, and monitored for absolute neutrophil count (ANC) before each cycle, grade and duration of neutropenia, incidence of neutropenic sepsis, treatment delays and requirements for secondary GCSF.
Positive_regulation (requirements) of GCSF in neutrophil
4) Confidence 0.44 Published 2008 Journal Breast Cancer Res. Treat. Section Body Doc Link 18060493 Disease Relevance 0.08 Pain Relevance 0
Another example supporting the role of cytokines in the pathogenesis of Sweet's syndrome is a patient with myelodysplastic syndrome-associated (non-granulocyte-colony stimulating factor-induced) Sweet's syndrome in whom elevated serum levels of granulocyte-colony stimulating factor and interleukin-6 were detected [128].
Positive_regulation (elevated) of granulocyte-colony stimulating factor in granulocyte associated with syndrome, myelodysplastic syndromes and cytokine
5) Confidence 0.28 Published 2007 Journal Orphanet J Rare Dis Section Body Doc Link PMC1963326 Disease Relevance 1.58 Pain Relevance 0.07
A recent study comparing patients with active and inactive Sweet's syndrome demonstrated significantly higher levels of serum granulocyte-colony stimulating factor in individuals whose dermatosis was active than in patients whose Sweet's syndrome was inactive [129].
Positive_regulation (levels) of serum granulocyte-colony stimulating factor in granulocyte associated with skin diseases and syndrome
6) Confidence 0.25 Published 2007 Journal Orphanet J Rare Dis Section Body Doc Link PMC1963326 Disease Relevance 1.41 Pain Relevance 0.15
Of these, 12 patients required granulocyte-colony stimulating factor (GCSF) and 5 patients were maintained at 75% of the original dose because of repetitive hematologic toxicities.
Positive_regulation (required) of GCSF in granulocyte
7) Confidence 0.12 Published 2008 Journal Yonsei Medical Journal Section Body Doc Link PMC2615369 Disease Relevance 0.98 Pain Relevance 0.04
PK analyses largely supported the bioequivalence of Hospira filgrastim and Amgen filgrastim.
Positive_regulation (bioequivalence) of filgrastim
8) Confidence 0.05 Published 2010 Journal Ann Hematol Section Body Doc Link PMC2924967 Disease Relevance 0 Pain Relevance 0
PK analyses largely supported the bioequivalence of Hospira filgrastim and Amgen filgrastim.
Positive_regulation (bioequivalence) of filgrastim
9) Confidence 0.05 Published 2010 Journal Ann Hematol Section Body Doc Link PMC2924967 Disease Relevance 0 Pain Relevance 0
Although tolerability of peginterferon-alpha 2a appears slightly superior, treatment was discontinued in 29% in one trial, despite the use of hematopoietic growth factors (granulocyte colony stimulating factor and erythropoietin) being allowed in this trial (Chung et al 2004).
Positive_regulation (allowed) of granulocyte colony stimulating factor in superior
10) Confidence 0.01 Published 2006 Journal International Journal of Nanomedicine Section Body Doc Link PMC2676642 Disease Relevance 1.24 Pain Relevance 0.12

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox